Introduction
============

Impaired brain function has long been recognized as a complication of COPD (see [@b13-copd-3-429] for a comprehensive review). While cognitive and mood changes in COPD have generally been associated with hypoxemia, much of the variance remains unexplained, particularly in highly heterogeneous or less well characterized subject samples. This exploratory study examines in detail the pathways from lung disease to brain dysfunction in a carefully selected group of COPD patients and matched controls, using disease-specific measures of disease severity and disability, validated measures of mood and cognition, plasma measures of proinflammatory cytokines, and both structural and neurochemical measures of brain integrity. As our intent was to construct a testable working model of COPD and the brain, we used a broad conceptual framework and inclusive measurement domains. Initial hypotheses were that COPD severity and requirement for oxygen supplementation would be related to poorer cognitive processing but not premorbid intelligence; to increased proinflammatory cytokines, a possible systemic mediator between lung and brain; and to signs of structural and neurochemical damage in brain regions known to be related to mild cognitive deficits and highly sensitive to oxygen deprivation (hippocampus and frontal lobes).

Methods
=======

Subjects were 18 patients with clinically stable COPD and 9 age- and gender-matched healthy controls, carefully screened to exclude persons with major chronic medical comorbidity or use of medications known to be associated with cognitive impairment. Clinical laboratory evaluation (CBC, extended chemistry panel including albumin) was normal for all included subjects and none was clinically cachectic (ie, all BMI \> 20). Pulmonary disease management had been optimized by the subject's usual pulmonary physician prior to enrollment; one subject awaiting lung transplantation was matched for surgery before completing the physiological components of the protocol. No COPD or control subject met diagnostic criteria for dementia, current major depression, primary panic disorder, or alcohol abuse, and none was a current smoker. [Table 1](#t1-copd-3-429){ref-type="table"} summarizes subject characteristics. Patients receiving supplemental oxygen used their normal prescribed daytime flow rates during all study procedures (cognitive and mood assessment, 6-minute walk, and all neuroimaging studies).

Measures of pulmonary function included spirometry, pulse oximetry at rest and change during a 6-minute walk, and distance walked ([@b7-copd-3-429]). Health status was assessed using the St George's Respiratory Disease Questionnaire (SGRQ; [@b15-copd-3-429]).

Cognitive measures included the Dementia Rating Scale-2 ([@b16-copd-3-429]), a measure of global cognitive functioning; the Wide Range Achievement Test-3 ([@b29-copd-3-429]), a measure of premorbid intelligence; the logical memory subtest of the WMS-3 ([@b27-copd-3-429]); and a measure of moment-to-moment cognitive processing sensitive to mild brain dysfunction, the Digit Symbol coding test ([@b28-copd-3-429]; [@b1-copd-3-429]; [@b17-copd-3-429]; [@b19-copd-3-429]).

Depression was assessed using two validated measures, the Hamilton Depression Rating Scale (Ham-D, 17 item version \[[@b23-copd-3-429]\], a symptom severity scale) and the PHQ-9 ([@b18-copd-3-429]), which yields both symptom severity and good reliability with diagnoses of major and minor depression. Anxiety was measured with the Patient-Rated Anxiety Scale (PRAS \[[@b25-copd-3-429]\]) which was previously found to be sensitive to both psychological anxiety/worry and somatic symptoms of sympathetic overarousal in COPD ([@b3-copd-3-429]).

A plasma cytokine panel was assayed on flash-frozen plasma collected after completion of questionnaires and cognitive tests. IL-1b, IL-2r, IL-6, TNFα, and hsCRP were measured using immunoassay kits (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA) on the Siemens Immulite (IL-1b, IL-2r, TNFα) and Siemens Immulite 2000 (hsCRP and IL-6). Measurement of the soluble TNFR1 (also known as TNFR-p55) receptor and TNFR2 (TNFR-p75) receptor was performed using enzyme immunoassay kits (Biosource International, Camarillo, CA, USA) run on the Roche COBAS Core II (Roche Diagnostics, Basel, Switzerland). The intra-assay and inter-assay coefficients of variation are generally \<5.0% for all assays over the entire assay range, and in no case \>10%, according to the reagent literature.

Neuroimaging was done on a different day separated by up to a week apart from cognitive, mood, 6-minute walk, and blood sample acquisition. Measures included structural magnetic resonance imaging (MRI) and neurochemical imaging with ^1^H magnetic resonance spectroscopy. A set of 3 dimensional, high-resolution (1.5 mm) T1-weighted coronal MRI images was acquired extending through the entire brain, using, a spoiled GRASS (SPGR) sequence (TE 5 ms and TR 35 2000 ms; field of view 24 cm; matrix size 256 × 256; flip angle 45°; NEX 1, interleaved with 0 gap). A set of axial FLAIR sequences extending through the entire brain was also acquired (TR 10,000 ms, TE 130 ms; TI 220; field of view 24 cm; matrix size 256 × 192, NEX1, 3 mm thick, interleaved with 0 gap). Global ratings of brain atrophy (T1) and subcortical white matter hyperintense lesions (FLAIR) were scored by two independent raters and any discrepancies reconciled before analysis. Hippocampal volume was measured using previously published quantitative methods ([@b2-copd-3-429]).

Neurochemical measures were collected in left frontal lobe white matter and left hippocampus using ^1^H MRS (voxel size 15 × 15 × 12 mm and TR/TE 2000/144 ms. MRS data were fit using custom basis sets in LCModel ([@b21-copd-3-429]) and quantified using a partial volume (tissue) corrected unsuppressed water signal. These methods yielded millimolar concentrations of N-acetylaspartate + N-acetylaspartyl-glutamate (NAA+), creatine (Cre, the sum of phophocreatine and creatine), and choline-containing compounds (Cho). The neurochemical measures have coefficients of variation in our hands ranging from 3.3% to 5.3% for NAA, Cre, and Cho respectively, and reproducibility is equivalent within and between sessions ([@b4-copd-3-429]).

Analytic approach and statistical methods
-----------------------------------------

All dependent measures (mood, cognition, cytokines, imaging variables) were first subjected to one-way ANOVAs comparing COPD and control subjects, and COPD oxygen users with non-users and controls. After identifying dependent variables associated with COPD group membership and/or oxygen use at the p \< 0.05 level (see [Table 2](#t2-copd-3-429){ref-type="table"}), stepwise multiple regression was used to determine which of the COPD variables were uniquely associated with observed group differences. Major variables describing the presence and severity of COPD were used to construct a "backbone" comprised of the following: presence or absence of COPD; SGRQ total score; FEV~1~% predicted; oxygen use; and 6-minute walk distance and maximum walking-related change in oxygen saturation (see [Figure 1](#f1-copd-3-429){ref-type="fig"}). The criteria for including a variable in the "backbone" were primarily clinical (based on the core measures used in COPD assessment and staging, eg, SGRQ, FEV~1~, oxygen dependence), while the sequential ordering of the backbone variables was statistical (see [Figure 1](#f1-copd-3-429){ref-type="fig"}). Variables were placed according to their strongest "near-neighbor" relationships in regressions. In regressions predicting mood, cognition, and brain imaging outcomes, in addition to the COPD backbone variables we also allowed stepwise entry of age, education and gender to control their potential confounding effects. The end result of all regressions is summarized in a final model showing R^2^ relationships between the relevant variables (see [Figure 1](#f1-copd-3-429){ref-type="fig"}). In the model, "mood" is a z-score composite of three highly intercorrelated scales (Ham-D, PHQ-9, and PRAS; all r = 0.7--0.8). To limit Type 1 statistical errors, and to increase clarity and robustness in the final model, only relationships with p ≤ 0.01 were included. This analytic approach simulates structural equation modeling, which is precluded here by small sample size.

Results
=======

Descriptive data for the sample are shown in [Table 1](#t1-copd-3-429){ref-type="table"}. Groups were well matched across demographic characteristics and showed the expected differences in the main lung disease related predictor (independent) variables. Group comparisons for key outcome (dependent) variables are shown in [Table 2](#t2-copd-3-429){ref-type="table"}. Statistically significant differences between controls and the whole COPD group were found for several cognitive and mood measures but not for brain structural or neuro-chemical measures. Both depression measures, the Ham-D and PHQ-9, showed group differences. PHQ-9 differed between control and combined COPD groups, whereas Ham-D scores increased linearly across the three groups from control (lowest) to hypoxemic/oxygen dependent (highest), an increase explained by items rating symptoms of physical disability rather than depressed mood (data not shown). Oxygen-dependent COPD patients fared worse than controls and nonoxygen-dependent COPD patients on cognitive as well as mood measures.

Brain atrophy, number and estimated volume of white matter hyperintensities, and frontal and hippocampal neuro-chemical indices, did not differ between COPD and control groups (not all data shown). Mean hippocampal volume was smaller in COPD subjects than controls, with oxygen-dependent patients having an 11% smaller volume, but these differences were not statistically significant in analyses across all subjects. On the other hand, frontal choline was significantly higher in oxygen dependent subjects, consistent with evidence of brain damage in this most impaired group.

Circulating proinflammatory cytokine levels were highly skewed and were therefore rank-transformed before analysis (data not shown). Only soluble TNFR1 showed significant group differences, with the highest levels in oxygen-dependent COPD subjects.

The working model constructed by stepwise regressions relating primary COPD variables with multidimensional outcome measures ([Figure 1](#f1-copd-3-429){ref-type="fig"}) shows the unique variance accounted for (R^2^) at each step.

Discussion
==========

This study replicates known relationships between measures of COPD disease severity, general cognition, and mood (Grant et al 1987) in a group of subjects with normal premor-bid intelligence and good educational attainment, selected for minimal medical comorbidity. It extends earlier findings on cognition using measures sensitive to mild cognitive impairment (digit symbol substitution). It also provides new insights into the mechanisms by which severe ambulatory stages of oxygen-dependent COPD may produce cumulative damaging effects on the brain. The chain linking oxygen desaturation during relatively low-intensity exercise (6-minute walk) to elevations in frontal choline, and then to changes in brain white matter, appears to be robust (R^2^ = 0.45--0.48). This elevation in brain choline levels cannot be attributed to acute oxygen desaturation during the 6-minute walk test, as spectroscopy was performed on a different day, and oxygen-dependent patients were transported to the scanner by wheelchair.

We propose that frequent oxygen desaturation during everyday activity may be a key mechanism underlying the damage to brain tissue reflected in elevated brain choline. Similar choline elevations are observed in systemic diseases secondarily associated with brain tissue breakdown and cognitive impairment ([@b10-copd-3-429], [@b9-copd-3-429]; [@b8-copd-3-429]), and appear to reflect damage to myelin and increased turnover of neuronal membrane precursors ([@b24-copd-3-429]). It is likely that increases in choline in advanced hypoxemic COPD reflect such a combination of membrane breakdown and turnover changes in the brain, and that these are eventually manifested as white matter hyperintensities on structural imaging. Other spectroscopy approaches (eg, decoupled ^31^P MRS) to measure individual constituents of the choline peak could be helpful in refining and further interpreting these results.

Elevation of frontal choline in oxygen-dependent COPD patients is consistent with the work of Incalzi et al (2003) using a different (perfusion) imaging approach. In that comprehensive mapping study, substantial perfusion deficits were identified in frontal lobes and were most marked in oxygen-dependent subjects. Only one previous study used ^1^H MRS to measure brain neurochemical species in patients with COPD ([@b26-copd-3-429]). Shim et al reported decreases in NAA, creatine, and choline in COPD subjects relative to controls, whereas we found no differences in NAA or creatine and an *elevation* in choline, and this was limited to oxygen-dependent subjects. However, in the Shim study, oxygen dependent subjects were excluded, participants were younger, analyses were not adjusted for age and education, and the brain regions sampled were different from those used in the present study and possibly less likely to be related to changes in mood and cognition.

In the present study, we also found evidence of chronic systemic inflammation, measured as an elevation of TNFR1, in chronically hypoxemic patients, an effect associated with exercise limitation (impaired 6-minute walk distance). We did not examine acute cytokine responses to exercise in this study; a previous study in 11 GOLD Stage IIb patients found an abnormally elevated systemic TNFα response to a single session of moderate acute exercise, but no acute effect of exercise on TNFR1 ([@b22-copd-3-429]). TNFR1, in contrast to TNFα, most likely reflects the presence of a chronic, but not acute, systemic inflammatory milieu. Such a milieu might be promoted by repeated inflammatory responses to everyday exertion in oxygen-dependent patients. This theory is consistent with data showing elevated TNFR1 levels in both typical inflammatory diseases (rheumatoid arthritis \[[@b11-copd-3-429]; [@b20-copd-3-429]\]) and diseases in which the role of chronic systemic inflammation has only recently emerged (eg, ischemic cardiovascular disease \[[@b5-copd-3-429]\]). These studies suggest that TNFR1 may be among the most sensitive indicators of long-term systemic inflammation in many different chronic diseases, now including COPD.

Implications
============

This study was designed to develop a testable multidimensional model of the emergence of brain dysfunction in patients living with COPD. Although many studies have found relationships between depression, anxiety, and cognition in COPD patients that are generally more apparent with greater disease severity, the present study explicitly traces a pathway leading from symptoms through objective measures of pulmonary disease to brain dysfunction that may occur with disease progression. We confirmed that the presence of COPD is associated with mild decrements in mood and cognition. Severe disease is associated with evidence of chronic systemic inflammation (elevated TNFR1) and subtle cognitive deficits (digit symbol). Levels of oxygen desaturation that are likely to occur with everyday activities in severe COPD appear to mediate specific changes in brain neurochemistry and structure that suggest sustained brain damage. The strong relationships we report in the working model presented here are likely to survive replication in larger samples, as the effect sizes we found for 14 of 15 R^2^ relationships qualify as large ([@b6-copd-3-429]).

The cross sectional model presented here would require testing in prospective research designs to evaluate its ability to predict longitudinal decline in cognition and incident damage to brain tissue integrity. However, such damage, once it has occurred, may not be reversible. While the evidence is limited, it appears that the cognitive impairment reported in advanced COPD is only partially reversible with oxygen therapy started late in the disease course ([@b12-copd-3-429]). If our model is correct, routine identification of episodic desaturation with everyday activity, and/or sleep, and earlier oxygen supplementation, could help to prevent irreversible brain damage in COPD patients.
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![Modeling the impact of COPD on brain function (R^2^ shown).\
Stepwise multiple regressions with "backbone" variables used as predictors of outcome variables already showing COPD group differences (see text). Numbers next to lines connecting domains indicate R^2^ for the relevant relationship. All effects shown are independent of age, education, and gender.\
**Variable definitions**\
Independent variables -- COPD backbone:\
Group: COPD vs control; Health status: total score, St. Georges Respiratory Questionnaire; FEV~1~: forced expiratory volume % predicted; Oxygen use: use/nonuse of supple mental oxygen; Walk distance: distance (feet) walked in 6 minutes (or to maximum tolerated, if less than 6 minutes); Desaturation with activity: resting SpO~2~ minus minimum SpO~2~ during walk.\
Dependent variables:\
Global cognition: total score, Dementia Rating Scale; Mood: z score combination of 17-item Hamilton Depression Scale, Patient Rated Anxiety Scale, and Patient Health Questionnaire-9; Attention: digit symbol substitution (WAIS); Chronic inflammation: soluble tumor necrosis factor receptor 1 (TNFR1); Frontal choline measured in frontal white matter by ^1^H MRS; White matter changes: subcortical white matter hyperintensities on MRI FLAIR images.](copd-3-429f1){#f1-copd-3-429}

###### 

Sample description

  Demographics                           Controls(n = 9)   COPD (n = 18)
  -------------------------------------- ----------------- ---------------------------------------------
  Age, mean years (SD)                   68.2 (5.8)        68.5 (8.0)
  Sex (% women)                          62%               64%
  Education, mean years (SD)             16.8 (2.8)        17.7 (2.5)
  Ethnicity (% white)                    100%              100%
  **Pulmonary disease indicators**                         
  GOLD stage (number × stage)                              
  IIa (FEV~1~ 50%--79% predicted)        na                2
  IIb (FEV~1~30%--49% predicted)         na                8
  III (FEV~1~\< 30% predicted)           na                7[a](#tfn1-copd-3-429){ref-type="table-fn"}
  SGRQ mean total (SD)                   6 (3)             56 (17)
  6 MWD, mean feet (SD)                  1545 (196)        922 (262)
  Long-term continuous O~2~ use (n, %)   0                 9 (53%)
  SpO~2~, mean resting (SD)              98.1 (1.5)        96.0 (2.2)
  SpO~2~, mean minimum during 6MW (SD)   94.6 (1.7)        88.0 (3.1)

1 subject dropped out for lung transplant before spirometry measures completed Analyses by 1-way ANOVA.

**Abbreviations:** SGRQ, St. George's Respiratory Disease Questionnaire total score (% possible disability points); 6 MWD, 6-minute walk distance; SpO~2~, O~2~ saturation by pulse oximeter.

###### 

Neuropsychiatric, neuroanatomical, and neurochemical measures (means and standard deviations)

  Domain                           Controls      COPD                        P control vs COPD
  -------------------------------- ------------- ------------- ------------- -------------------------------------------------
  WRAT-3                           109.1 (9.8)   109.1 (5.9)   103.7 (8.3)   ns
  DRS-2 Total                      12.3 (3.2)    9.0 (3.3)     9.9 (2.2)     0.019
  Memory                           11.9 (1.7)    10.3 (2.7)    9.6 (2.8)     0.049
  WAIS-3                                                                     
  Digit symbol                     12.7 (1.5)    12.1 (1.5)    8.4 (3.3)     0.034[a](#tfn4-copd-3-429){ref-type="table-fn"}
  WMS-3                                                                      
  Logical memory                   13.7 (2.1)    12.6 (2.1)    10.7 (3.1)    0.049[b](#tfn5-copd-3-429){ref-type="table-fn"}
  **Mood (depression, anxiety)**                                             
  Ham-D 17                         3.4 (2.9)     8.4 (3.3)     12.2 (5.7)    0.001[c](#tfn6-copd-3-429){ref-type="table-fn"}
  PHQ-9                            1.3 (1.2)     6.1 (6.2)     6.1 (4.1)     0.005
  PRAS                             2.8 (3.0)     22.0 (20.7)   29.3 (19.2)   0.002
  **Brain structure**                                                        
  Hippocampal volume               5.4 (0.9)     5.2 (0.8)     4.8 (0.8)     ns
  White matter lesions             2.0 (0.0)     2.7 (0.8)     2.0 (0.9)     ns
  **Neurochemistry**                                                         
  Frontal choline                  3.96 (0.38)   3.30 (0.46)   4.50 (0.71)   ns[d](#tfn7-copd-3-429){ref-type="table-fn"}
  Hippocampal NAA+                 12.6 (1.8)    11.9 (2.0)    13.0 (1.7)    ns
  **Inflammation**                                                           
  Soluble TNFR1                    2.14 (0.50)   2.37 (0.97)   2.71 (0.62)   0.03

All comparisons by 1-way ANOVA with post-hoc tests; p \> 0.05 reported as ns. For cognitive tests, age/education scaled scores reported. For mood scales, total scores reported. Hippocampal volume reported as cubic centimeters for right and left hippocampus combined. White matter lesions reported as relative predominance of subcortical vs periventricular hyperintensities. Soluble TNF R1 reported as ng/mL.

O~2~ users worse than both other groups (p ≤ 0.005).

O~2~ users borderline worse than both other groups (p = 0.05--0.10).

All groups significantly different (p = 0.001).

O~2~ users worse than nonusers and controls (p ≤ 0.005).
